menu
    • menu
    [{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Pieris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Cinrebafusp alfa","moa":"CD137","graph1":"Oncology","graph2":"Preclinical","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Pieris Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Seagen \/ Pieris Pharmaceuticals"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tucatinib","moa":"HER2 tyrosine kinase","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tucatinib","moa":"HER2 TK","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Merck & Co. Inc","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Merck & Co. Inc"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tucatinib","moa":"HER2 TK","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Tucatinib

    Menu

    Tucatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tucatinib,Trastuzumab Emtansine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TUKYSA® (tucatinib) in Combination with Antibody-Drug Conjugate ado-Trastuzumab Emtansine Improves Progressio...

                            Details : TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.

                            Brand Name : Tukysa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 06, 2023

                            Lead Product(s) : Tucatinib,Trastuzumab Emtansine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tucatinib,Kadcyla

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Seagen Phase 3 Trial of TUKYSA (tucatinib) in Combination with Antibody-Drug Conjugate Ado-trastuzumab Emtansi...

                            Details : TUKYSA (tucatinib) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein and in combination with ado-trastuzumab emtansine is being developed in patients with HER2-positive metastatic or unresectable breast cancer.

                            Brand Name : Tukysa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 16, 2023

                            Lead Product(s) : Tucatinib,Kadcyla

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tucatinib,Trastuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Seagen Announces FDA Accelerated Approval of Tukysa® (tucatinib) in Combination with Trastuzumab for People w...

                            Details : Tukysa (tucatinib) is a TKI of HER2, inhibiting phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell proliferation, and showed antitumor activity in HER2 expressing tumor cells in combination with trastu...

                            Brand Name : Tukysa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 19, 2023

                            Lead Product(s) : Tucatinib,Trastuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tucatinib,Trastuzumab,Oxaliplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Seagen Announces TUKYSA® (tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previ...

                            Details : In vivo (in living organisms), TUKYSA (tucatinib) inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab showed increased anti-tumor activity in vitro and in vivo compared to either medicine alone...

                            Brand Name : Tuksya

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 19, 2022

                            Lead Product(s) : Tucatinib,Trastuzumab,Oxaliplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tucatinib,Trastuzumab,Oxaliplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity...

                            Details : At a median duration of follow-up of 20.7 months, results of MOUNTAINEER trial showed a 38.1% cORR per blinded independent central review in HER2-positive patients who were assigned to receive Tuksya (tucatinib) in combination with trastuzumab.

                            Brand Name : Tuksya

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 02, 2022

                            Lead Product(s) : Tucatinib,Trastuzumab,Oxaliplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tucatinib,Capecitabine,Trastuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cancer Symposium

                            Details : Pivotal HER2CLIMB trial showed that TUKYSA resulted in a robust and durable prolongation of overall survival that was consistent with results from the primary analysis for HER2-positive metastatic breast cancer patients with brain metastases.

                            Brand Name : Tukysa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 19, 2021

                            Lead Product(s) : Tucatinib,Capecitabine,Trastuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Zymeworks

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Zymeworks

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zanidatamab,Tucatinib,Capecitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Breast Cancer At The San Antonio Breas...

                            Details : Zanidatamab is a bispecific antibody, based on Zymeworks’ Azymetric™ platform. Zymeworks is developing zanidatamab in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that e...

                            Brand Name : ZW25

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 19, 2021

                            Lead Product(s) : Zanidatamab,Tucatinib,Capecitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Zymeworks

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed

                            Zymeworks

                            Canada arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zanidatamab,Tucatinib,Capecitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient with HER2-Ve+ Breast Cancer Dosed with Zanidatamab Tukysa Combo

                            Details : Zanidatamab binds to HER2 across a range of expression levels and has demonstrated multiple mechanisms of action including the formation of receptor clusters, resulting in receptor internalization and downregulation that affect signal transduction .

                            Brand Name : ZW25

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 28, 2021

                            Lead Product(s) : Zanidatamab,Tucatinib,Capecitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cinrebafusp alfa,Tucatinib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Pieris Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Pieris Announces Amendment of Existing Collaboration with Seagen to Evaluate Cinrebafusp Alfa in Combination w...

                            Details : Pieris' option to co-develop and co-commercialize the second of 3 programs in the collaboration has been amended to provide it with a co-promotion option in the U.S, with Seagen solely responsible for the development and overall commercialization of that...

                            Brand Name : PRS-343

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 25, 2021

                            Lead Product(s) : Cinrebafusp alfa,Tucatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Pieris Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Seagen

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tucatinib

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            EC Approves Seagen’s TUKYSA® for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positiv...

                            Details : Patients who received TUKYSA in combination with trastuzumab and capecitabine in the pivotal trial had a 46 percent reduction in the risk of cancer progression or death compared to patients who received trastuzumab and capecitabine alone.

                            Brand Name : Tukysa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 12, 2021

                            Lead Product(s) : Tucatinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth